SpringWorks Therapeutics Inc.

Merck KGaA has broken its silence regarding rumors of a takeover bid for SpringWorks Therapeutics and stated that talks to buy the US-based cancer and rare disease specialist are well advanced. Reacti

Merck KGaA only has two-late stage candidates in its pipeline but CEO Belén Garijo has told Scrip that the German company is laser-focused on adding more assets. Speaking at Merck’s annual press con

SpringWorks Therapeutics has received US approval for its second commercial product just a day after Merck KGaA confirmed rumors that it was in advanced negotiations to acquire the US biotech. SpringW

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. B+L Bolsters Ophthalmology With Acquis